

# Sara MarcÃ³ Costa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8857521/publications.pdf>

Version: 2024-02-01

13  
papers

724  
citations

840776

11  
h-index

1199594

12  
g-index

13  
all docs

13  
docs citations

13  
times ranked

1016  
citing authors

#	ARTICLE	IF	CITATIONS
1	FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Molecular Medicine, 2018, 10, .	6.9	176
2	Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. Journal of Clinical Investigation, 2013, 123, 3254-3271.	8.2	176
3	Correction of Pathological Accumulation of Glycosaminoglycans in Central Nervous System and Peripheral Tissues of MPSIIIA Mice Through Systemic AAV9 Gene Transfer. Human Gene Therapy, 2012, 23, 1237-1246.	2.7	102
4	CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome). JCI Insight, 2016, 1, e86696.	5.0	56
5	Liver Production of Sulfamidase Reverses Peripheral and Ameliorates CNS Pathology in Mucopolysaccharidosis IIIA Mice. Molecular Therapy, 2012, 20, 254-266.	8.2	51
6	Biochemical, histological and functional correction of mucopolysaccharidosis Type IIIB by intra-cerebrospinal fluid gene therapy. Human Molecular Genetics, 2015, 24, 2078-2095.	2.9	48
7	Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID. Human Molecular Genetics, 2017, 26, 1535-1551.	2.9	39
8	<i>In Vivo</i> Gene Therapy for Mucopolysaccharidosis Type III (Sanfilippo Syndrome): A New Treatment Horizon. Human Gene Therapy, 2019, 30, 1211-1221.	2.7	25
9	Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal. Molecular Therapy - Methods and Clinical Development, 2021, 23, 370-389.	4.1	16
10	Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy. Nature Communications, 2021, 12, 5343.	12.8	15
11	Progressive neurologic and somatic disease in a novel model of human Mucopolysaccharidosis type IIIC. DMM Disease Models and Mechanisms, 2016, 9, 999-1013.	2.4	14
12	AAV-mediated BMP7 gene therapy counteracts insulin resistance and obesity. Molecular Therapy - Methods and Clinical Development, 2022, 25, 190-204.	4.1	6
13	348. Correction of CNS and Somatic Pathology by Intra-Cerebrospinal Fluid Gene Therapy for Mucopolysaccharidosis Type II. Molecular Therapy, 2016, 24, S139.	8.2	0